Oslo, 24 September 2012 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the results from the first-in-man study of Amphinex in combination with the generic cytotoxic agent bleomycin will be presented at the ESMO (European Society for Medical Oncology) 2012 Congress, Vienna, Austria (28 September - 2 October 2012).
The study was performed at University College Hospital (UCH) London, UK. There were no unexpected side effects and the treatment showed promising early signs of efficacy across a range of tolerable doses.
Poster title: First-in-man Phase I study of TPCS2a-based photochemical internalisation (PCI) of bleomycin in locally recurrent or advanced/metastatic, cutaneous or subcutaneous malignancies
Presented by Dr. Martin Forster (UCH)
Monday 1 October 2012, 13:00-14:00 (CET)
Hall XL, Austria Center Vienna
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021
About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed drug delivery system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When these are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.
PCI Biotech focuses on the clinical development of Amphinex® in combination with cancer drugs for localised cancer treatment, based on the company's unique drug delivery platform.
Amphinex® is developed in combination with the generic cytotoxic agent bleomycin for head & neck cancer and the generic cytotoxic agent gemcitabine for bile duct cancer.
A preclinical program for the use of PCI to enhance the effect of vaccines is ongoing, with the aim to start a clinical study.
The study was performed at University College Hospital (UCH) London, UK. There were no unexpected side effects and the treatment showed promising early signs of efficacy across a range of tolerable doses.
Poster title: First-in-man Phase I study of TPCS2a-based photochemical internalisation (PCI) of bleomycin in locally recurrent or advanced/metastatic, cutaneous or subcutaneous malignancies
Presented by Dr. Martin Forster (UCH)
Monday 1 October 2012, 13:00-14:00 (CET)
Hall XL, Austria Center Vienna
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021
About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed drug delivery system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When these are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.
PCI Biotech focuses on the clinical development of Amphinex® in combination with cancer drugs for localised cancer treatment, based on the company's unique drug delivery platform.
Amphinex® is developed in combination with the generic cytotoxic agent bleomycin for head & neck cancer and the generic cytotoxic agent gemcitabine for bile duct cancer.
A preclinical program for the use of PCI to enhance the effect of vaccines is ongoing, with the aim to start a clinical study.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.